Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Efficacy, safety and surgical management with concizumab prophylaxis in three young patients affected by severe hemophilia with inhibitorsHuman Clinical Trial · 2026 · 1 citations
2Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 studyRCT · 2026
3Concizumab prophylaxis for haemophilia A or B without inhibitors: a plain language summary of the phase 3 explorer8 studyLate-Phase Clinical Trial · 2026
4Concizumab plasma concentration measurements for personalized dose adjustment in patients with Hemophilia A/B with and without inhibitors: Data from the Phase 3 explorer7 and explorer8 studies2025 · 1 citations
5Association of Patient-Reported Outcomes with Hemophilia A Inhibitor Status and Treatment Product TypeReview · 2026
6The Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference2024 · 12 citations
7Minimal interference of concizumab with standard clinical coagulation laboratory assays – An in vitro study2024 · 3 citations
8Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status2025
9Perinatal outcomes of direct oral anticoagulant exposure during pregnancy: An analysis of the French pharmacovigilance databaseResearch and Practice in Thrombosis and Haemostasis · 2026
10Antithrombotic Strategies for Thrombosis Treatment and Thromboprophylaxis in Pediatric Cardiac Disease: A 20-Year Systematic Review of Prospective Studies and Clinical TrialsResearch and Practice in Thrombosis and Haemostasis · 2026

More from Research and Practice in Thrombosis and Haemostasis

More from Monash University